Aetna modified CPB 1031 for tofersen (Qalsody), effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its tofersen (Qalsody) coverage policy under CPB 1031 Aetna system, effective September 26, 2025. This drug — an antisense oligonucleotide therapy for SOD1-ALS — bills under HCPCS J1304 and requires precertification for all participating providers. If your practice administers tofersen or handles revenue cycle for neurology or specialty infusion, this policy has direct financial exposure.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Tofersen (Qalsody) — CPB 1031 |
| Policy Code | CPB 1031 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Neurology, Specialty Infusion, Molecular Pathology, Rare Disease |
| Key Action | Confirm precertification is in place and verify GCIT network designation before administering tofersen |
Aetna Tofersen (Qalsody) Coverage Criteria and Medical Necessity Requirements 2025
The Aetna tofersen coverage policy under CPB 1031 is built around a narrow, well-defined indication. Tofersen treats amyotrophic lateral sclerosis caused by a confirmed SOD1 gene mutation — ICD-10-CM G12.21. That molecular confirmation is not optional. It's a hard prerequisite.
Genetic testing for the SOD1 gene mutation bills under CPT 81404 (Molecular pathology procedure, Level 5, full gene sequence SOD1). If your patient doesn't have documented SOD1 mutation results in the record before you submit for precertification, expect a medical necessity denial. Get the genetic testing completed and the results in the chart first.
Tofersen itself is delivered intrathecally — directly into the central nervous system via spinal puncture. That administration bills under CPT 96450 (Chemotherapy administration, into CNS, requiring and including spinal puncture). The drug billing is separate: HCPCS J1304 covers the injection at one unit per 1 mg of tofersen administered. Track your dose carefully. Billing J1304 at the wrong unit count is a fast path to a claim denial.
Prior authorization is required on all commercial Aetna plans. There are no exceptions for participating providers. Call (866) 752-7021 or fax your Statement of Medical Necessity to (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| ALS with confirmed SOD1 mutation | Covered | J1304, G12.21, CPT 96450 | Prior authorization required; SOD1 mutation must be documented |
| SOD1 genetic testing to confirm eligibility | Covered (related) | CPT 81404 | Required as part of medical necessity documentation |
| Intrathecal administration of tofersen | Covered (when criteria met) | CPT 96450 | Requires spinal puncture; bills separately from drug |
| ALS without confirmed SOD1 mutation | Not Covered | G12.21 | Mutation confirmation is a hard prerequisite |
Aetna Tofersen Billing Guidelines and Action Items 2025
This is where most revenue cycle teams will have gaps. Tofersen billing touches three separate code types — drug, administration, and diagnostic — and adds a site-of-care requirement that can void reimbursement entirely if you miss it.
| # | Action Item |
|---|---|
| 1 | Confirm GCIT network status before September 26, 2025. Unless your member's health plan has opted out, tofersen must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) designated site. Administer at a non-designated site and you're looking at a denied claim regardless of prior auth status. Check the Aetna Institutes® GCIT Designated Networks page and confirm your facility qualifies. |
| 2 | Submit precertification before the first dose. Precertification is required for all Aetna commercial members. Call (866) 752-7021 or fax (888) 267-3277. Have the SOD1 mutation documentation, the prescribing neurologist's notes, and your SMN form ready. Incomplete submissions slow down approval and delay treatment. |
| 3 | Verify SOD1 mutation documentation is in the chart. CPT 81404 (Level 5 molecular pathology, full gene sequence SOD1) needs to appear in the medical record before you seek prior authorization for J1304. If the genetic test was done elsewhere, get the records. Aetna's medical necessity review will look for this. |
| 4 | Set up J1304 charge capture at the correct unit count. J1304 bills at 1 mg per unit. Tofersen is typically dosed at 100 mg, which means 100 units of J1304 per administration. Audit your charge capture setup now. Under-billing loses revenue; over-billing creates a compliance problem. |
| 5 | Bill CPT 96450 separately for each intrathecal administration. The administration procedure — spinal puncture and CNS delivery — bills under CPT 96450. This is not bundled into J1304. Confirm your billing team knows to submit both codes on the same date of service. |
| 6 | Check the member's plan design for GCIT opt-outs. Some Aetna plan designs elect not to require the GCIT network designation. Know your member's plan before assuming network requirements apply. This distinction matters for site-of-care decisions and reimbursement. |
| 7 | For Medicare members, use a different workflow entirely. CPB 1031 covers commercial plans only. Medicare criteria for tofersen are governed by separate Aetna Medicare Part B rules. If you're billing for a Medicare Advantage member, check Aetna's Medicare Part B step criteria — the commercial CPB 1031 billing guidelines do not apply. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Tofersen (Qalsody) Under CPB 1031
HCPCS Codes Covered When Selection Criteria Are Met
| Code | Type | Description |
|---|---|---|
| J1304 | HCPCS | Injection, tofersen, 1 mg |
Supporting CPT Codes Related to CPB 1031
These codes are not the primary drug billing codes, but they're directly tied to the clinical pathway for tofersen and will appear on claims or pre-authorization documentation.
| Code | Type | Description |
|---|---|---|
| 81404 | CPT | Molecular pathology procedure, Level 5; includes full gene sequence SOD1 (superoxide dismutase 1, soluble) |
| 96450 | CPT | Chemotherapy administration, into CNS (e.g., intrathecal), requiring and including spinal puncture |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| G12.21 | Amyotrophic lateral sclerosis |
G12.21 is the only ICD-10 diagnosis code listed in CPB 1031. Every claim for J1304 and CPT 96450 should carry G12.21 as the primary diagnosis. If your documentation supports a more specific coding path, confirm with your compliance officer before deviating from this code.
The Real Billing Risk Here
Let's be direct about what makes tofersen billing harder than most specialty drug claims.
You have three separate billing events — genetic testing (CPT 81404), drug administration (CPT 96450), and drug cost (J1304) — that may happen at different facilities, on different dates, and through different revenue channels. Molecular pathology labs may bill CPT 81404 separately. Infusion sites bill CPT 96450. The drug itself may be specialty pharmacy-dispensed and billed through a different workflow entirely.
If those three billing streams aren't coordinated, you'll see split documentation, mismatched dates of service, and prior auth gaps. A claim denial on J1304 at $10,000+ per dose isn't a minor write-off.
The GCIT designation requirement adds another layer. This is the same pattern Aetna uses for gene therapies like CAR-T — a site-of-care restriction that functions as a quiet coverage exclusion if you're not paying attention. Treating at a non-designated site without a documented plan-level opt-out means you're outside the coverage policy, full stop.
If you're managing tofersen billing across multiple sites or your team is setting this up for the first time, loop in your compliance officer before the effective date of September 26, 2025. The financial exposure per patient is significant, and the administrative requirements are specific enough that a single missed step creates a denial that's hard to overturn.
Get the Full Picture for CPT 81404
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.